Extended versus standard lymphadenectomy in patients undergoing pancreaticoduodenectomy for periampullary adenocarcinoma

Extended versus standard lymphadenectomy in patients undergoing pancreaticoduodenectomy for periampullary adenocarcinoma ? a prospective randomized single center trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN59390953

Enrollment

120

Registered

2014-11-07

Start date

2006-01-09

Completion date

Unknown

Last updated

2015-07-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic cancer: periampullary adenocarcinoma, including tumors of the pancreatic head, the distal common bile duct and the ampulla of Vater Cancer

Interventions

Surgery: Patients underwent pancreaticoduodenectomy with standard (SLA) or Extended (ELA) lymphadenectomy. SLA is defined as lymphadenectomy of the anterior and posterior lymph nodes of the pancreatic

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with confirmed diagnosis or suspicion of a periampullary adenocarcinoma, including tumors of the pancreatic head, the distal common bile duct and the ampulla of Vater.

Exclusion criteria

Exclusion criteria: 1. Age <18 years and metastatic disease 2. Unresectability of the tumor 3. Absence of malignancy in the final histology

Design outcomes

Primary

Measure	Time frame
Local progression free survival. Directly after 9 and 18 months, a CT scan is performed. With this CT scan any local recurrence of the tumour and distant metastases can be detected.	—

Secondary

Measure	Time frame
1. Overall survival 2. Morbidity	—

Countries

Germany

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026